Mortality after colorectal cancer among survivors of childhood cancer.
1/5 보강
Mortality after diagnosis of colorectal subsequent malignant neoplasms (CRC-SMN) among childhood cancer survivors is understudied.
- HR 2.51
APA
Major A, Chou J, et al. (2026). Mortality after colorectal cancer among survivors of childhood cancer.. Journal of the National Cancer Institute, 118(3), 545-549. https://doi.org/10.1093/jnci/djaf127
MLA
Major A, et al.. "Mortality after colorectal cancer among survivors of childhood cancer.." Journal of the National Cancer Institute, vol. 118, no. 3, 2026, pp. 545-549.
PMID
40838867 ↗
Abstract 한글 요약
Mortality after diagnosis of colorectal subsequent malignant neoplasms (CRC-SMN) among childhood cancer survivors is understudied. Using data from the Childhood Cancer Survivor Study (CCSS) and the Surveillance, Epidemiology, and End Results (SEER) program, we compared all-cause mortality of survivors with CRC-SMN with survivors without CRC-SMN and CRC patients in the general population without a childhood cancer history. Among 25 656 childhood cancer survivors, 96 developed CRC-SMN, with 50% diagnosed before age 40 years and 19% before age 30 years. Of those diagnosed before age 40 years, 35% had no prior abdominal- or pelvic-directed radiation therapy. The cumulative incidence of CRC-SMN in CCSS survivors was 0.7% (95% CI = 0.5% to 0.9%) by age 45 years and 1.1% (95% CI = 0.8% to 1.4%) by age 50 years. There were 31 deaths after CRC-SMN. Adjusted all-cause mortality was threefold higher (hazard ratio [HR] = 3.34, 95% CI = 2.25 to 4.59) than for survivors without CRC and statistically significantly higher for survivors diagnosed younger than age 30 years compared with SEER CRC patients (HR = 2.51, 95% CI = 1.29 to 4.89).
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.